A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer. Cohort 1 will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic the

Trial Details

NCT ID

NCT04524871

Phase

PHASE1 / PHASE2

Sponsor

Hoffmann-La Roche

Status

RECRUITING

Cancer Type

Hepatocellular Carcinoma (HCC) Liver Cancer

Interventions

Atezolizumab
Bevacizumab 15 mg/kg
Tiragolumab
Tocilizumab
TPST-1120
Tobemstomig 2100 mg

Locations (sample)

Costa Mesa, California, United States|33.64113,-117.91867
Duarte, California, United States|34.13945,-117.97729
Orange, California, United States|33.78779,-117.85311
San Diego, California, United States|32.71571,-117.16472
San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 within 7 days prior to randomization
Locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) with diagnosis confirmed by histology/cytology or clinically by A…
Liver Diseases criteria in cirrhotic patients
Child-Pugh class A within 7 days prior to randomization

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →